Cas No.: | 857402-63-2 |
Chemical Name: | [(3R,5S,6R,7S,8E,10S,11S,12Z,14E)-6,20,22-trihydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16-oxo-21-(prop-2-enylamino)-17-azabicyclo[16.3.1]docosa-1(22),8,12,14,18,20-hexaen-10-yl] carbamate;hydrochloride |
Synonyms: | IPI504; IPI-504; IPI504; Retaspimycin; Retaspimycin HCl; Retaspimycin hydrochloride |
SMILES: | Cl.C=CCNC1=C(O)C=C2NC(C(=CC=CC([C@H](C(=C[C@@H]([C@H]([C@H](C[C@@H](CC1=C2O)C)OC)O)C)C)OC(=O)N)OC)C)=O |t:11,13,17,&1:17,20,21,22,24| |
Formula: | C31H46ClN3O8 |
M.Wt: | 624.17 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | A water-soluble derivative of 17-AAG and HSP90 inhibitor; induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.Lung CancerPhase 2 Discontinued |